

gis maga maga ada a sa gis Maga a Maga a San

Marco Bianchi
Senior Vice President
NYSE Liffe US
20 Broad Street, 10th Floor
New York, NY 10005
T +1 212 656 4300

By Electronic Mail

September 27, 2013

Mr. David A. Stawick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT REQUESTED

D۵.

NYSE Liffe US Submission 2013-124 – Designated Market Maker (DMM) program in Futures on the MSCI ACWI, MSCI ACWI Ex-US, MSCI Emerging Markets Asia Indices and Lead Market Maker (LMM) program in Futures on the MSCI Emerging Markets Asia Index

Dear Mr. Stawick:

I am the Senior Vice President of Market Development of NYSE Liffe US LLC ("NYSE Liffe US" or the "Exchange"). Pursuant to Section 5c(c) of the Commodity Exchange Act, as amended (the "Act"), and U.S. Commodity Futures Trading Commission (the "Commission") Regulations Section 40.6(a), I enclose a Cover Sheet for NYSE Liffe US Submission 2013-124 and NYSE Liffe US Notice 28/2013 which announces the Designated Market Maker ("DMM") program in Futures on the MSCI ACWI, MSCI ACWI Ex-US, MSCI Emerging Markets Asia Indices and the Lead Market Maker ("LMM") program in Futures on the MSCI Emerging Markets Asia Index (collectively "mini MSCI Index Futures") effective with the October 15, 2013, trading session.

NYSE Liffe US hereby certifies that: (i) the DMM and LMM program announced in Notice 28/2013 comply with the Act and the Regulations and (ii) a notice and copy of this submission is being concurrently posted on the Exchange's web site. Additionally, a concise explanation and analysis of the DMM and LMM programs and their compliance with applicable provisions of the Act, including the Core Principles and the Regulations, is attached. No substantive opposing views were expressed by members or others with respect to the DMM and LMM programs.

The manufacture of the second second

If you have any questions, please call me at (212) 656-4312.

Yours Truly,

Marco Bianchi Enclosures



Karl D. Cooper Chief Regulatory Officer Market Regulation Department NYSE Liffe US 20 Broad Street, 10th Floor New York, NY 10005 (212) 656-4568

CONFIDENTIAL TREATMENT REQUEST BY NYSE LIFFE US LLC

By Electronic Mail

September 27, 2013

Linda J. Mauldin
Paralegal Specialist
FOIA Compliance Office
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT REQUESTED

Re: Confidential Treatment Request

Dear Ms. Mauldin:

By e-mail dated today, September 27, 2013, NYSE Liffe US LLC ("NYSE Liffe US" or the "Exchange") in connection with NYSE Liffe US Submission 2013-124, voluntarily provided the supplemental information attached.

n gradalik

对 持续执行

Pursuant to Commission Rule 145.9(d), the Exchange requests confidential treatment of the information attached and this letter on the grounds that disclosure of this information would reveal confidential commercial or financial information of the Exchange. Pursuant to Commission Rule 145.9(d)(5) the Exchange requests that confidential treatment of the attached information be maintained until further notice from the Exchange. The Exchange requests that the Commission notify it immediately after receiving any request under the Freedom of Information Act ("FOIA") or any other court order, subpoena or summons for the attached information. The Exchange specifically notes that it does not waive in any manner its rights under Section 8(f) of the Commodity Exchange Act to receive a copy of any subpoena or summons for the attached information prior to the Commission's disclosure of such information pursuant to such subpoena or summons. Finally, the Exchange requests that the Commission notify it in the event that the Commission intends to disclose the attached information to Congress or any federal or state governmental agency or department.

In connection with this request for confidential treatment, and pursuant to Commission Rule 40.8, the Exchange is submitting the attached detailed written justification in support of the request for confidential treatment.

opsåmy kryption State

A15. . . .

If you have any questions, please call me at (212) 656-4568.

Faithfully yours,

Karl Dooper

Enclosure